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EDCl is a novel glycoprotein, mol wt 27,000, isolated 
in 1976 from leukemic urine. It inhibits the serine pro-
teases trypsin and chymotrypsin and is antigenically 
related to interalpha trypsin inhibitor (IATI), mol wt 
170,000, a normal plasma antiprotease. Since psoriasis is 
a non neoplastic hyperproliferative state, we have now 
measured EDCI by a specific radioimmunoassay (RIA) in 
plasma and urine of 24 untreated psoriatic patients. 
EDCl was not detectable in normal urine (< 1 mg/gm 
creatinine) or plasma (< 1 mg/L). 55% of psoriatic urine 
specimens were positive by RIA, containing 8 to 110 mg/ 
gm creatinine. 75% of plasmas were positive, containing 
12 to 32 mg/L. Plasma and urine contents of EDCl were 
significantly (P < .05) correlated with severity of clinical 
disease (% skin involved) but not with age, sex, distri-
bution or type of lesion, family history or arthritis. 
EDCI is a novel glycoprotein, mol wt 27,000, which was 
isolated in 1976 from the urine of a patient with acute myelo-
cytic leukemia [1). The protein was named after the patient, 
ED, from whose urine it was first isolated; Cl refers to the 
sequence of chromatographic steps involved in its purification. 
T his protein inhibits the action of trypsin and chymotrypsin 
[2]. It is antigenically related to the normal human plasma 
antiproteolytic protein "inter alpha trypsin inhibitor," mol wt 
170,000 [3). 
Normal individuals excrete <1 mg EDCI in the urine per day 
[1,4]. EDCI is not detectable in normal plasma (<1 mg/ L) . In 
contrast, about 80% of patients with metastatic cancer of 7 
different types excrete >lO mg/day of the glycoprotein [4). The 
EDCl-proteinuria results from an accumulation of the glyco-
protein in cancer plasma (30 to 100 mg/L) [4). 
Patients with non-neoplastic acute and chronic illness, in 
general, do not show detectable EDCl-proteinuria, and the 
protein is not detectable in their plasma [ 4). In 1976 we tested 
the first patient with psoriasis encountered in this project and 
found EDCJ-proteinuria. Accordingly, a study was undertaken 
to measure plasma and urine EDCl in a series of 24 patients 
with psoriasis. 
METHODS 
I . Subjects 
Twenty-four subjects with psoriasis were selected at random from a 
private dermatology practice. All exhibited characteristic chronic scal-
ing erythematous psoriasiform lesions. Clinical details are summarized 
in the Table. 
For comparative purposes, 9 healthy volunteers (5 males, 4 females) 
age 19 to 36 were also studied. 
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2. Measurement of EDCl Concentration. 
As a qualitative screening test, the presence or absence of ED !-
proteinuria was determined by double immunodiffusion analysis (DID) 
of the urine [1,51- Quantitative analysis of EDCI concentration in urine 
and plasma was done by radioimmunoassay (RIA) as described previ-
ously [I]. The plasma samples were chromatographed on a Sephadex 
G-75 column (I em X 160 em) and the fractions eluting at position 
corresponding to EDCI were analyzed by RIA [ I]. This step separated 
EDCI from the antigenically related interalpha trypsin inhibitor (lATl) . 
Preliminary studies showed EDCI excretion in psoriatic patients varied 
from the daily average by less than ± 15% through the day. Therefore 
in the present study spot urine samples were analyzed for ED 1 and 
also for creatinine (4), and the degree of EDCI proteinuria was ex-
pressed as mg/gm creatinine. 
RESULTS 
As previously reported [ l ], normal urine was negative in the 
DID test and contained < 1 mg EDCI/gm creatinine by RIA. 
Normal plasma contained < 1/ mg/L of the glycoprotein. 
As the Table shows, 9 of 22 (41 %) urine specimens were 
positive by DID and 12 of22 (55%) were positive by RIA (range, 
<1-110; median 8). Sixteen of 22 (73%) plasmas were positive 
by RIA (range, <10-32; median 15). This illustrates the relative 
sensitivity of the techniques used. The urine DID is the least 
sensitive test, and RIA examination of plasma the most sensi-
tive technique, with the urine RIA falling in between. 
Significant rank correlations (P < .05) were obtained between 
plasma RIA, urine RIA and urine DID. (i) When plasma EDCl 
was < 10 mg/L (the limit of sensitivity of the technique), urine 
RIA and urine DID were both negative. (ii) When plasma E DCl 
was in the range 11 to 14 mg/L, the urine RIA were positive at 
8 and 23 mg/gm creatinine but urine DID was negative. (iii) 
When plasma EDCI was > 15 mg/ L, urine RIA was > 1 mg/g 
creatinine and urine DID was positive in all but one subject. 
Comparisons of medians were made for (i) plasma EDCI and 
urine EDCl RIA values, and (ii) the clinical features of the 
pso riatic patients using the Mann-Whitney test. No significan t 
differences (P < .05) were apparent between EDCl levels and 
age, sex, distribu tion or type of lesion, family history or pre ence 
of arthri tis. However, the EDCl values showed a significant 
direct relationship to severity of disease (P < .05). 
DISCUS ION 
EDCI i not detectable in the pia rna or urine of normals or 
patients with most non neoplastic diseases [1]. In disseminated 
cancer, the glycoprotein appears in the plasma, and is excreted 
by the kidneys into the urine with a clearance equal to 4% that 
of creatinine [ 4]. Degree of EDCI-proteinuria is generally pro-
portional to anatomic stage of the cancer [ 4). Remission and 
relapse of the neoplastic disease are accompanied by disap-
pearance and reappearance of EDCI-proteinuria respectively 
[6). The glycoprotein is antigenically related to, and is probably 
a fragment of, the normal plasma anti protease lA TI (3]. 
The mechanism of formation of EDCl is not established but 
the following hypothesis has been suggested. Cancer cells have 
an abnormally large content of proteases, including one which 
activates plasminogen [7). The tumorigenic and metastatic 
potential of cancer cells is generally proportional to their pro-
teolytic activity [8). When proteases are engaged by antipro-
teases, fragmentation of the latter often occurs. If IATI interacts 
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Summary of the clinical data of patients and their plasma and 
urinary EDCileuels 
Urine EDCI 
Plasma 
Pnt Age Sex Severity" EDCI RIA Double (meg/ L) (mg/g lmmuno· 
creatinine) diffusion 
1 52 F Mild 14 23 
2 65 M Mild < 10 < I 
3 48 M Mild 18 45 + 
4 66 M Mild < 10 <1 
5 54 F Mild II <I 
6 32 F Mild < 10 <1 
7 44 F Mild < 10 <I 
8 23 F Mild 14 8 
9 44 M Mild < 10 < I 
10 33 M Mild 12 <I 
II 3 F Mod 15 57 + 
12 36 M Mod 28 73 + 
13 49 M Mod 25 49 + 
14 25 F Mod 14 <I 
15 77 F Mod <10 <I 
16 28 F Mod 32 42 + 
17 28 F Mod 17 8 
18 58 F Mod 15 <1 
19 64 M Sev 20 65 + 
20 35 F Sev 30 110 + 
21 48 M Sev 27 84 + 
22 24 F Sev 22 45 + 
" Mild, moderate and severe are defined as <10%, 10-35%, and >35% of 
body surface involved by p oriatic lesion . 
specifically with cancer cell proteases, EDCl could be one 
product of this interaction. 
Finnish workers have recently found augmented serine pro-
teases, including one which activates plasminogen, in psoriatic 
compared to normal epidermis [9]. They suggested that this 
increment of activity could be related in the same way to 
proliferation of psoriatic skin as enhanced plasminogen activity 
is related to proliferation of cancer cells. The present fmding of 
EDCl accumulation in plasma and urine of psoriatic patients 
supports this analogy. Evidently there is a similar type of 
disturbance in the proteolytic activity of cancer and psoriatic 
cells, and in the interaction of IATI with each type of cell. 
Whether this disorder in cellular metabolism is the result of 
excessively rapid cell multiplication, or whether it is the cause 
of this multiplication, remains a subject for future investigation. 
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